

Claims

1. Use of pipamperon for the preparation of a medicament for treating a disease or disorder with an underlying dysregulation of the emotional functionality, wherein said pipamperon is administered to a patient in a dose ranging between 5 and 15 mg of the active ingredient, and wherein a second compound is administered simultaneously with, separate from or sequential to said pipamperon to augment the therapeutic effect of said second compound.
2. Use according to claim 1, wherein said pipamperon is administered daily at least one day before administering said second compound.
3. Use according to any of claims 1 to 2, wherein said second compound affects the monoaminergic transmitter system.
4. Use according to claim 3, wherein said second compound is selected from the group comprising: 5-HT reuptake enhancer, 5-HT1 autoreceptor agonist, 5HT1A receptor agonist, 5-HT1A receptor antagonist, 5-HT1B receptor antagonist, 5-HT2B receptor antagonist, 5-HT2C receptor antagonist, 5-HT3 receptor antagonist, 5-HT6 receptor antagonist, adrenergic transmitter releaser, α_1 adrenoreceptor antagonist, α_2 adrenoreceptor antagonist, β_3 adrenoreceptor agonist, cannabinoid receptor antagonist, D1 receptor agonist, D2 receptor antagonist, D3 receptor antagonist, DA uptake inhibitor, dopamine receptor agonist, H3 receptor antagonist, compounds which increase brain concentrations of 5-HT, levodopa, MAO reuptake inhibitor, MAO-A & MAO-B reuptake inhibitor, MAO-B inhibitor, MAO-B re-uptake inhibitor, NARI, NaSSA, NDRI, RIMA, SDA, SDRI, Second messenger beta agonist, SNDRI, SNRI and SSRI.
5. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases or disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, substance related disorder, personality disorders, antisocial behaviour, bereavement, occupational problem and problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable

salt thereof is administered simultaneously with, separate from or prior to the administration of a 5-HT (serotonin) reuptake enhancer compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said 5-HT (serotonin) reuptake enhancer compound, further characterized in that pipamperon is to
5 be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

6. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-
10 cognitive mental disease or disorder selected from the group of diseases or disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, substance related disorder, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a 5-HT1 autoreceptor agonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said 5-HT1 autoreceptor agonist compound,
15 further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

7. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-
20 cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender disorders, sleep disorders, adjustment disorders, impulse control disorders, attention-deficit disorders, substance-related disorder, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a 5-HT1A (serotonin 1A) receptor agonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said 5-HT1A (serotonin) 1A receptor agonist compound, further characterized in that
25
30
35

pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

8. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender disorders, adjustment disorders, impulse control disorders, substance-related disorder, personality disorders, antisocial behaviour, bereavement, occupational problem and problems related to abuse or neglect, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a 5-HT1A receptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said 5-HT1A receptor antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

9. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender disorders, sleep disorders, adjustment disorders, impulse control disorders, substance-related disorder, personality disorders, antisocial behaviour, bereavement, occupational problem and problems related to abuse or neglect, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a 5-HT1B receptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said 5-HT1B receptor antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

10. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders

consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender disorders, sleep disorders, adjustment disorders, impulse control disorders, substance-related disorder, personality disorders, antisocial behaviour,

5 bereavement, occupational problem, problems related to abuse or neglect and pain disorders characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a 5-HT2B receptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said 5-HT2B receptor antagonist compound,
10 further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

11. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender disorders, sleep disorders, adjustment disorders, impulse control disorders, substance-related disorder, personality disorders, antisocial behaviour,
20 bereavement, occupational problem, problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a 5-HT2C receptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said 5-HT2C receptor antagonist compound,
25 further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

12. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of substance-related disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a 5-HT3 receptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said 5-HT3 receptor antagonist compound, further characterized in that pipamperon is to be administered to a patient in a
35 daily dose ranging between 5 and 15 mg of the active ingredient.

13. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a cognitive disorder selected from the group of diseases and disorders consisting of Alzheimer Disease, substance-induced persisting dementia, vascular dementia, dementia
5 due to HIV disease, dementia due to head trauma, dementia due to Parkinson Disease, dementia due to Huntington Disease, dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease, amnestic disorders due to a general medical condition, substance-induced persisting amnestic disorder, mild cognitive impairment disorder and other cognitive disorders, characterized in that pipamperon or said pharmaceutically
10 acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a 5-HT6 receptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said 5-HT6 receptor antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

15 14. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome,
20 somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, adjustment disorders, impulse control disorders, personality disorders, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of an adrenergic transmitter releaser compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said adrenergic transmitter releaser compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

25 30 15. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders,

impulse control disorders, personality disorders, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a alpha 1 adrenoreceptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said alpha 1 adrenoreceptor antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

10 16. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, psychotic disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious 15 disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, substance related disorders, personality disorders, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a alpha 2 adrenoreceptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said alpha 2 adrenoreceptor antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

25 17. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative 30 disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, substance related disorders, personality disorders, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a beta 3 adrenoreceptor agonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said beta 3 adrenoreceptor agonist compound,

further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

18. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting mood disorders, anxiety disorders, psychotic disorders, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sleep disorders, adjustment disorders, impulse control disorders, pervasive development disorders, disruptive behaviour disorders, substance-related disorders, personality disorders, psychological factors affecting medical conditions, malingering, antisocial behaviour, bereavement, occupational problem, identity problem and problems related to abuse or neglect, pain disorders and delirium, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a cannabinoid receptor 1 antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said cannabinoid receptor 1 antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

19. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of substance related disorders and Parkinson disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a D1 receptor receptor agonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said D1 receptor receptor agonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

20. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting mood disorders, psychotic disorders, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sleep disorders, adjustment disorders, impulse control disorders, pervasive development disorders, disruptive

behaviour disorders, substance-related disorders, personality disorders, psychological factors affecting medical conditions, malingering, antisocial behaviour, bereavement, occupational problem, identity problem and problems related to abuse or neglect, pain disorders and delirium, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a D2 receptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said D2 receptor antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

10

21. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of psychotic disorders, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sleep disorders, adjustment disorders, impulse control disorders, pervasive development disorders, disruptive behaviour disorders, substance-related disorders, personality disorders, psychological factors affecting medical conditions, malingering, antisocial behaviour, bereavement, occupational problem, identity problem, problems related to abuse or neglect, pain disorders and delirium, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a D3 receptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said D3 receptor antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

22. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of substance related disorders and Parkinson disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a DA (dopamine) uptake inhibitor compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said DA (dopamine) uptake inhibitor compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

23. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, adjustment disorders, impulse control disorders, attention-deficit disorders, substance-related disorders, personality disorders and problems related to abuse or neglect, pain disorder and Parkinson disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a dopamine receptor agonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said dopamine receptor agonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

15

24. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a cognitive mental disease or disorder selected from the group of diseases and disorders consisting of Alzheimer Disease, substance-induced persisting dementia, vascular dementia, dementia due to HIV disease, dementia due to head trauma, dementia due to Parkinson Disease, dementia due to Huntington Disease, dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease, amnestic disorders due to a general medical condition, substance-induced persisting amnestic disorder, mild cognitive impairment disorder and other cognitive disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a histamine H₃receptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said histamine H₃receptor antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

30

25. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative

35

disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, substance-related disorders, personality disorders, bereavement, occupational problem, problems related to abuse or neglect and pain disorder, characterized in that pipamperon or said pharmaceutically acceptable salt

5 thereof is administered simultaneously with, separate from or prior to the administration of a compound which increases brain concentrations of 5-HT (serotonin) to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said compound which increases brain concentrations of 5-HT (serotonin), further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15

10 mg of the active ingredient.

26. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Parkinson Disease, characterized in that pipamperon or said pharmaceutically acceptable
15 salt thereof is administered simultaneously with, separate from or prior to the administration of a levodopa/decarboxylase inhibitor compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said levodopa/decarboxylase inhibitor compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

20

27. A pharmaceutical composition comprising (a) pipamperon, and (b) a levodopa/decarboxylase inhibitor compound, preferably is (eti)levodopa/carbidopa, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof in combination with entacapone, which is an inhibitor of catechol-O-methyltransferase (COMT), or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, as a combined preparation for simultaneous, separate or sequential use for treating the underlying emotion dysregulation of Parkinson Disease.
25

30

28. A pharmaceutical composition according to claim 27, wherein pipamperon is provided in a unitary dose of between 5 and 15 mg of the active ingredient and wherein said levodopa/decarboxylase inhibitor compound is levodopa / carbidopa, preferably provided in a unitary dose of between 250 to 600 mg and 25 to 150 mg of the active ingredients.

35

29. A pharmaceutical composition according to claim 27, wherein pipamperon is provided in a unitary dose of between 5 and 15 mg of the active ingredient and wherein

said levodopa/decarboxylase inhibitor compound is levodopa / benserazide, preferably provided in a unitary dose of between 100 to 600 mg and 25 to 150 mg of the active ingredients.

5 30. A pharmaceutical composition according to any of claims 27 or 28, wherein pipamperon is provided in a unitary dose of between 5 and 15 mg of the active ingredient and wherein said levodopa/decarboxylase inhibitor compound is levodopa / carbidopa or etilevodopa / carbidopa in combination with entacapone, of which the latter is preferably provided in a unitary dose of between 500 mg and 100 mg of the active ingredient.

10

31. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of non-cognitive mental disease or disorder which are substance related disorders and Parkinson disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a monoamine oxidase (MAO) reuptake inhibitor compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said monoamine oxidase (MAO) reuptake inhibitor compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

15

20

32. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, adjustment disorders, impulse control disorders, attention-deficit disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorder, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a monoamine oxidase A (MAO-A) and a monoamine oxidase B (MAO-B) reuptake inhibitor compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said monoamine oxidase A (MAO-A) and a monoamine oxidase B (MAO-B) reuptake inhibitor compound, further characterized in that pipamperon is to be

25

30

35

administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

33. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, adjustment disorders, impulse control disorders, attention-deficit disorders, substance-related disorders, personality disorders, problems related to abuse or neglect, pain disorder and Parkinson disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a monoamine oxidase B (MAO-B) inhibitor compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said monoamine oxidase B (MAO-B) inhibitor compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

34. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Parkinson Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a monoamine oxidase B (MAO-B) reuptake inhibitor to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said monoamine oxidase B (MAO-B) reuptake inhibitor, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

35. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, adjustment disorders, attention-deficit disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorder, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a selective nor-

adrenaline re-uptake inhibitor (NARI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective nor-adrenaline re-uptake inhibitor (NARI) compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

5

36. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a noradrenergic/specific serotonergic antidepressant (NaSSA) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said noradrenergic/specific serotonergic antidepressant (NaSSA) compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

20

37. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, adjustment disorders, attention-deficit disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a selective nor-adrenaline and dopamine re-uptake inhibitor (NDRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective nor-adrenaline and dopamine re-uptake inhibitor (NDRI) compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

38. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome,
5 somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, adjustment disorders, impulse control disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, characterized in that
10 pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a compound which is a reversible inhibitor of mono-amine oxydase A (RIMA) to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said compound which is a reversible inhibitor of mono-amine oxydase A (RIMA), further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active
15 ingredient.

39. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, psychotic disorders, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sleep disorders, adjustment disorders, impulse control disorders, pervasive development disorders, disruptive behaviour disorders, substance-related disorders, personality disorders, psychological factors affecting medical conditions, malingering, antisocial behaviour, bereavement, occupational problem, identity problem, problems related to abuse or neglect, pain disorder and delirium, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a serotonin/dopamine antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said
25 serotonin/dopamine antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active
30 ingredient.

40. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders
35

consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sleep disorders, adjustment disorders, impulse control disorders, substance-related disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect, pain disorders, delirium, Alzheimer Disease, substance-induced persisting dementia, vascular dementia, dementia due to HIV disease, dementia due to head trauma, dementia due to Parkinson Disease, dementia due to Huntington Disease, dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease, amnestic disorders due to a general medical condition, substance-induced persisting amnestic disorder, mild cognitive impairment disorder and other cognitive disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a selective serotonin and dopamine re-uptake inhibitor (SDRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective serotonin and dopamine re-uptake inhibitor (SDRI) compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

41. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, personality disorders, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a second messenger beta agonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said second messenger beta agonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

42. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders

consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sleep disorders, adjustment disorders, impulse control disorders, attention-deficit disorders, substance-related disorders, personality disorders, antisocial behaviour, 5 bereavement, occupational problem, problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic 10 effect of said selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

43. Use of pipamperon or a pharmaceutically acceptable salt thereof for the 15 preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sleep disorders, adjustment disorders, impulse control disorders, attention-20 deficit disorders, substance-related disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound to augment 25 the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

30 44. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative 35 disorders, sleep disorders, adjustment disorders, impulse control disorders, substance-related disorders, personality disorders, antisocial behaviour, bereavement, occupational

problem, problems related to abuse or neglect and pain disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a selective serotonin re-uptake inhibitor (SSRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective serotonin re-uptake inhibitor (SSRI) compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

5 45. Use according to claim 1 or 2, wherein said disease or disorder is Alzheimer
10 disease.

15 46. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a 5-HT6 antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said 5-HT6 antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

20 47. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of an acetylcholinesterase inhibitor compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said acetylcholinesterase inhibitor compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

25 30 48. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of an AMPA receptor mediator compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said AMPA receptor mediator

compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

49. Use of pipamperon or a pharmaceutically acceptable salt thereof for the
5 preparation of a medicament for treating the underlying emotion dysregulation of
Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable
salt thereof is administered simultaneously with, separate from or prior to the
administration of an amyloid aggregation-inhibitor compound to augment the therapeutic
effect or to provide a faster onset of the therapeutic effect of said amyloid aggregation-
10 inhibitor compound, further characterized in that pipamperon is to be administered to a
patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

50. Use of pipamperon or a pharmaceutically acceptable salt thereof for the
preparation of a medicament for treating the underlying emotion dysregulation of
15 Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable
salt thereof is administered simultaneously with, separate from or prior to the
administration of a calcium channel modulator compound to augment the therapeutic
effect or to provide a faster onset of the therapeutic effect of said calcium channel
modulator compound, further characterized in that pipamperon is to be administered to a
20 patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

51. Use of pipamperon or a pharmaceutically acceptable salt thereof for the
preparation of a medicament for treating the underlying emotion dysregulation of
Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable
salt thereof is administered simultaneously with, separate from or prior to the
25 administration of a choline uptake enhancer compound to augment the therapeutic effect
or to provide a faster onset of the therapeutic effect of said choline uptake enhancer
compound, further characterized in that pipamperon is to be administered to a patient in a
daily dose ranging between 5 and 15 mg of the active ingredient.

30 52. Use of pipamperon or a pharmaceutically acceptable salt thereof for the
preparation of a medicament for treating the underlying emotion dysregulation of
Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable
salt thereof is administered simultaneously with, separate from or prior to the
35 administration of a compound that activates ERK (extracellular signal-related kinase) to
augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said

compound that activates ERK (extracellular signal-related kinase), further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

5 53. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a GABA agonist compound to augment the therapeutic effect or to
10 provide a faster onset of the therapeutic effect of said GABA agonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

15 54. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a histamine H3-receptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said histamine
20 H3-receptor antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

25 55. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a compound which increases insulin sensitivity to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said compound
30 which increases insulin sensitivity, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

35 56. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable

salt thereof is administered simultaneously with, separate from or prior to the administration of a compound which mimics the effect of nerve growth factor (NGF) to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said compound which mimics the effect of nerve growth factor (NGF), further characterized in
5 that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

57. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of
10 Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a muscarinic receptor partial agonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said muscarinic receptor partial agonist compound, further characterized in that pipamperon is to be
15 administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

58. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of
20 Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a selective nor-adrenaline and dopamine re-uptake inhibitor (NDRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective nor-adrenaline and dopamine re-uptake inhibitor (NDRI)
25 compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

59. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of
30 Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to nerve growth factor (NGF) gene therapy, to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said nerve growth factor (NGF) gene therapy, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging
35 between 5 and 15 mg of the active ingredient.

60. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a nicotinic receptor agonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said nicotinic receptor agonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

5

10 61. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of an N-Methyl-D-aspartate (NMDA) antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said N-Methyl-D-aspartate (NMDA) antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

15

20 62. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a non-steroidal anti-inflammatory drug to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said a non-steroidal anti-inflammatory drug, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

25

30 63. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a phosphodiesterase-4 (PDE4) inhibitor compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said phosphodiesterase-4 (PDE4) inhibitor compound, further characterized in that pipamperon

35

is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

64. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a peptidic compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said peptidic compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

65. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a compound which protects dopaminergic and cholinergic neurons to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said compound which protects dopaminergic and cholinergic neurons, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

66. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a selective serotonin and dopamine reuptake inhibitor (SDRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective serotonin and dopamine reuptake inhibitor (SDRI) compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

67. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of Alzheimer Disease, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the

administration of a selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound, further characterized in that pipamperon is to be
5 administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

68. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, substance related disorders, personality disorders,
10 bereavement, occupational problem and problems related to abuse or neglect, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a CRF1 antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said CRF1 antagonist compound, further characterized in that
15 pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
20

69. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, substance-related disorders, personality disorders,
25 bereavement, occupational problem and problems related to abuse or neglect, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a GR antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said GR antagonist compound, further characterized in that
30 pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
35

70. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders
5 consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, substance-related disorders, personality disorders, bereavement, occupational problem and problems related to abuse or neglect,
10 characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a melatonin receptor (MT) agonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said melatonin receptor (MT) agonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose
15 ranging between 5 and 15 mg of the active ingredient.

71. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders
20 consisting of mood disorders, anxiety disorders, psychotic disorders, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sleep disorders, adjustment disorders, impulse control disorders, pervasive development disorders, disruptive behaviour disorders, substance-related disorders, personality disorders, psychological factors affecting medical conditions, malingering, antisocial
25 behaviour, bereavement, occupational problem, identity problem and problems related to abuse or neglect, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a neurotensin receptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said neurotensin receptor
30 antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

72. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders
35 consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome,

somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, substance-related disorders, personality disorders, bereavement, occupational problem and problems related to abuse or neglect,
5 characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a neurokinin 2 receptor (NK2) antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said neurokinin 2 receptor (NK2) antagonist compound, further characterized in that pipamperon is to be administered to a
10 patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

73. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders
15 consisting of mood disorders, anxiety disorders, psychotic disorders, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sleep disorders, adjustment disorders, impulse control disorders, pervasive development disorders, disruptive behaviour disorders, substance-related disorders, personality disorders, psychological factors affecting medical conditions, malingering, antisocial behaviour, bereavement, occupational problem, identity problem and problems related to abuse or neglect, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a neurokinin 3 receptor (NK3) antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said neurokinin 3
20 receptor (NK3) antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active
25 ingredient.

74. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders,
30 impulse control disorders, personality disorders, bereavement, occupational problem and problems related to abuse or neglect, characterized in that pipamperon or said
35

pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a peptidic compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said peptidic compound, further characterized in that pipamperon is to be administered to a patient in a daily dose
5 ranging between 5 and 15 mg of the active ingredient.

75. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders
10 consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, substance-related disorders, personality disorders, bereavement, occupational problem and problems related to abuse or neglect,
15 characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a substance P receptor (NK1) antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said substance P receptor (NK1)
20 antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

76. Use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders
25 consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, substance-related disorders, personality disorders, bereavement, occupational problem and problems related to abuse or neglect,
30 characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a tachykinin antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said tachykinin antagonist compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging
35 between 5 and 15 mg of the active ingredient.

77. Use according to any of claims 1 to 4 or 7, wherein said second compound is gepirone.

78. A method for preparing a compound having a selective D4 and 5-HT2A antagonist, 5 reverse agonist or partial agonist activity comprising the following steps: (a) measuring the selective affinity of a test compound to the D4 receptor and selecting a compound that has a pKi value equal to or greater than 8 towards the D4 receptor in respect to all the other D receptors, and measuring the selective efficacy of the selected compound to the D4 receptor and selecting a compounds which is a selective antagonist, inverse agonist or 10 partial agonist of the D4 receptor; (b) measuring the selective affinity of a test compound to the 5-HT2A receptor and selecting a compound that has a pKi value equal to or greater than 8 towards the 5-HT2A receptor in respect to all the other 5HT receptors, and measuring the selective efficacy of the selected compound to the 5-HT2A receptor and selecting a compounds which is a selective antagonist, inverse agonist or partial agonist 15 of the 5-HT2A receptor; (c) identifying a compound which is selected in (a) and (b), (d) preparing the compound identified in (c).

79. Compound prepared by the method of claim 78.

80. Use according to any of claims 1, 2 or 7, wherein said second compound is chosen from the group consisting of fluvoxamine controlled release, phenserine tartrate, atomoxetine hydrochloride, bupropion (controlled-release formulation), ropinirole HCL (controlled-release formulation), INN 00835, galantamine (extended release formulation), paliperidone, tomoxetine, aprepitant, rivastigmine tartrate, ORG 34517/34850, sunepitron, 25 sumanirole, milnacipran, idazoxan, xaliproden, SR 58611, befloxatone, litoxetine, tianeptine, agomelatine, SPD 503, flesinoxan, bifeprunox, ramelteon, etilevodopa, rasagiline (TVP-1012) and desvenlafaxine.

81. Use according to any of claims 1, 2 or 7, wherein said second compound is 30 chosen from the group consisting of galantamine (extended release formulation), R121919, risperidone, paliperidone and R228060 (YKP-10A).